Bank of New York Mellon Corp lifted its stake in shares of CryoLife, Inc. (NYSE:CRY) by 3.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 353,029 shares of the medical equipment provider’s stock after purchasing an additional 10,682 shares during the quarter. Bank of New York Mellon Corp owned 1.06% of CryoLife worth $7,042,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in shares of CryoLife by 0.7% during the 2nd quarter. Rhumbline Advisers now owns 57,291 shares of the medical equipment provider’s stock worth $1,143,000 after purchasing an additional 387 shares in the last quarter. First Mercantile Trust Co. grew its holdings in shares of CryoLife by 5.6% during the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after purchasing an additional 291 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of CryoLife by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 14,254 shares of the medical equipment provider’s stock worth $284,000 after purchasing an additional 200 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of CryoLife by 30.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 149,791 shares of the medical equipment provider’s stock worth $2,989,000 after purchasing an additional 35,247 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of CryoLife during the 2nd quarter worth $291,000. 68.44% of the stock is currently owned by institutional investors.

Shares of CryoLife, Inc. (CRY) opened at 22.70 on Friday. The company has a 50-day moving average price of $20.14 and a 200 day moving average price of $18.49. CryoLife, Inc. has a 1-year low of $14.03 and a 1-year high of $23.35. The firm has a market capitalization of $759.22 million, a price-to-earnings ratio of 68.79 and a beta of 0.97.

CryoLife (NYSE:CRY) last posted its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $47.02 million. During the same period in the previous year, the business earned $0.13 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. On average, equities research analysts predict that CryoLife, Inc. will post $0.43 EPS for the current year.

CRY has been the topic of several analyst reports. Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Thursday, June 8th. BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $22.00.

In related news, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares in the company, valued at $8,800,633.91. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James P. Mackin sold 125,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the transaction, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 169,050 shares of company stock valued at $3,724,225. 6.00% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/01/bank-of-new-york-mellon-corp-has-7-04-million-stake-in-cryolife-inc-cry.html.

CryoLife Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.